Literature DB >> 1710080

Immunohistochemical features of giant cell carcinoma of the lung: patterns of expression of cytokeratins, vimentin, and the mucinous glycoprotein recognized by monoclonal antibody A-80.

G Chejfec1, A Candel, D S Jansson, W H Warren, G K Koukoulis, J E Gould, G L Manderino, G T Gooch, V E Gould.   

Abstract

Giant cell carcinoma of the lung (GCCL) is an uncommon and extremely aggressive variant of lung cancer. Characteristic microscopic findings include marked pleomorphism, aggregates of mononucleated or multinucleated giant cells (or both), a general lack of architectural cohesiveness, extensive necrosis, and endocytosis by the giant cells. Although the epithelial character of GCCL has been confirmed by a number of studies, controversy persists as to whether it represents a variant of poorly differentiated adenocarcinoma or of squamous carcinoma. Histochemical studies for mucosubstances have yielded variable and conflicting results. This report describes conventionally fixed and processed samples from 10 cases of GCCL studied with a panel of monoclonal antibodies (Mabs) recognizing different cytokeratin polypeptides (AE1, AE3, AE1/AE3 cocktail, and CAM 5.2), vimentin, and Mab A-80, the last of which binds to a mucinous glycoprotein associated with exocrine differentiation. All 10 cases of GCCL reacted with all cytokeratin Mabs; the extent and intensity of the reaction varied notably. All cases stained strongly and diffusely with Mab AE1 and AE1/AE3, the reaction was less extensive and weaker with CAM 5.2. Significantly, 2 cases reacted focally with Mab AE3. Nine cases reacted extensively and intensely with the vimentin Mab, often showing prominent paranuclear globular profiles. All cases reacted with Mab A-80; the reaction was often strong, but the extent was variable. Findings indicate that all GCCL are indeed cytokeratin positive but that most express polypeptides toward the low-molecular weight end of the spectrum; a small subset also expresses heavier polypeptides.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1710080     DOI: 10.3109/01913129109016231

Source DB:  PubMed          Journal:  Ultrastruct Pathol        ISSN: 0191-3123            Impact factor:   1.094


  3 in total

Review 1.  [Lung cancer. Developments, concepts and preview of the new WHO classification].

Authors:  I Petersen; A Warth
Journal:  Pathologe       Date:  2014-11       Impact factor: 1.011

Review 2.  Lung cancer: developments, concepts, and specific aspects of the new WHO classification.

Authors:  Iver Petersen; Arne Warth
Journal:  J Cancer Res Clin Oncol       Date:  2015-07-22       Impact factor: 4.553

3.  Postmortem Investigation of Immunohistochemical Staining and Gross Description of Sarcomatoid Carcinoma of the Lung in a Patient With Extreme Leukemoid Reaction.

Authors:  Ali Ammar; Austin Ellis; Julia Hegert; Timothy W Jones; Rumi Khan
Journal:  J Investig Med High Impact Case Rep       Date:  2019 Jan-Dec
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.